Page 247 - index.html

3P07.03

CASE-CONTROL STUDY NESTED IN A PROSPECTIVE
COHORT OF MICROBIOME FOUND IN CIRRHOTIC
PATIENTS WITH AND WITHOUT HEPATOCELLULAR
CARCINOMA.

* 1
2
3
2
Federico Piñero , Martín Vazquez , Patricia Baré , Mariela Sciara , Manuel
Mendizabal , Cristian Rohr , Cristina Alonso , Fabian Fay , Marcelo Silva 1
1
2
2
1
1 Liver Unit, Hospital Universitario Austral, Pilar, HERITAS, Rosario, IMEX, CONICET,
2
3
National Academy of Medicine., Buenos Aires, Argentina
Corresponding author’s email: fpinerof@cas.austral.edu.ar
Introduction: Changes in microbiome have been described in patients with cirrhosis.
Although in murine models, a pro-oncogenic role of intestinal microbiome has been
observed, no specific microbiome profile in patients with hepatocellular carcinoma (HCC)
has been reported to date.
Aims: We aimed to compare microbiome found in cirrhotic patients with or without ePOSTER ABSTRACTS
HCC.

Material and Methods: From child Pugh A/B cirrhotic patients who were prospectively
followed up, patients with HCC (cases) were matched with controls in a 1:1 ratio according
to age, gender, aetiology and severity of portal hypertension. Computed Tomography
or Magnetic Resonance Imaging discarded HCC in all controls. Exclusion criteria:
immunosuppression, active alcoholism, prior or concomitant use of pre/probiotics, other
active neoplasm, current antibiotic treatment, diarrhoea, any malabsortion disorder or
inflammatory bowel disease. A sample of faecal stool was collected noninvasively at any
time of the day and store in -70°. Each sample was aliquoted for final processing and DNA
extraction using QIAmp DNA Stool Mini Kit. Sequencing of the V3-V4 region of the
16S rRNA gene was performed on the Illumina MiSeq Platform. Bioinformatics analysis
of the data was done using a custom QIIME pipeline (http://qiime.org/). Microbiome
assessment was performed blinded from any clinical data.

Results: From 407 cirrhotic patients, 25/25 cases and well-matched controls were
included. Baseline characteristic were age 64 ± 8 years, 88% males, body mass index
(BMI) 28 ± 4 kg/m2, hepatitis C virus 26%, Child Pugh A/B 74% and 26%, respectively.
Barcelona Clinic Liver Cancer stages in HCC patients were 0 (n=2), A (n=12), B (n=5)

EASL HCC Summit • Geneva, Switzerland • 2-5 February, 2017 247